Matthew P Kosloski

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Monoclonal Antibody

Atopic Dermatitis

Top Venues

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Marc R McCann, Matthew P Kosloski, Christine Xu, John D Davis, Mohamed A Kamal
Dupilumab: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (8) (2024)
Matthew P Kosloski, Emma Guttman-Yassky, Michael J Cork, Margitta Worm, Dong Ho Nahm, Xiaoping Zhu, Marcella K Ruddy, Sivan Harel, Mohamed A Kamal, Hélène Goulaouic, Christine R Xu, Elena Avetisova, John D Davis, Michael C Nivens, Arsalan Shabbir, Allen Radin
Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials. Clinical and translational science 17 (8) (2024)
Marc R McCann, Matthew P Kosloski, Christine Xu, John D Davis, Mohamed A Kamal
Dupilumab: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (8) (2024)
Matthew P Kosloski, Emma Guttman-Yassky, Michael J Cork, Margitta Worm, Dong Ho Nahm, Xiaoping Zhu, Marcella K Ruddy, Sivan Harel, Mohamed A Kamal, Hélène Goulaouic, Christine R Xu, Elena Avetisova, John D Davis, Michael C Nivens, Arsalan Shabbir, Allen Radin
Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials. Clinical and translational science 17 (8) (2024)
Matthew P Kosloski, Hong Li, Stanley Wang, Federico Mensa, Jens Kort, Wei Liu
Characterizing complex and competing drug-drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine. Clinical and translational science (2023)
Matthew P Kosloski, Hong Li, Stanley Wang, Federico Mensa, Jens Kort, Wei Liu
Characterizing Complex and Competing Drug-Drug Interactions Between the Antiviral Regimen of Glecaprevir and Pibrentasvir with Rifampin or Carbamazepine. Clinical and translational science (2023)